Bristol-Myers Squibb (BMY) wins FDA nod to expand the U.S. label for its blockbuster immunotherapy Opdivo in lung cancer.

On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $53.76 which represents a slight increase of $0.86 or 1.63% from the prior close of $52.9. The stock opened at ...

Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...

A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?

Bristol Myers Squibb (BMY) closed at $54.20 in the latest trading session, marking a +0.82% move from the prior day. This change outpaced the S&P 500's 0.17% loss on the day. Meanwhile, the Dow lost 0 ...

With a drug in advanced testing for two different indications that have spawned several blockbuster drugs, could Alumis be ...

Today, FMI President and CEO Leslie Sarasin issued the following statement: "Shoppers may be worried about their grocery needs due to the ongoing strike by the International Longshoremen's Association ...

Sun Life U.S. and DentaQuest, part of Sun Life U.S., are supporting relief efforts in the states most severely impacted by Hurricane Helene. The support will go to multiple organizations, including ...

The cuts follow an ongoing wave of staff reductions at big drug companies. Pharma giants have terminated thousands of ...

WARN notices filed with the state show more job cuts due in the health sector as companies look to cut costs and streamline ...

If we earn tomorrow’s dividend and then get assigned at expiration on October 25, we will earn $1.65 per share on $52.95 per ...

HALIX, a Dutch contract development and manufacturing organisation (CDMO) specialising in complex therapeutic antibodies and ...